What does this research mean for the field?

Anti-CD20 monoclonal antibodies provide a safe and effective treatment for IgA nephropathy with minimal change disease that extends recurrence-free periods compared to prolonged steroids, while circulating anti-nephrin autoantibodies serve as a predictive biomarker for disease relapse. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The aim was to assess the efficacy of anti-CD20 monoclonal antibodies and the prevalence of anti-nephrin antibodies in MCD-IgAN patients.

May 29, 2026Kidney International ReportsOpen Access

Anti-CD20 therapies and anti-nephrin autoantibodies in IgA nephropathy with minimal change disease

View Full Paper

Ask AI

Bookmark

Authors

YLYu Liang ZYZerui Yang XYXiaohan Yuan

Discussion

Member takes

Overview

Randomized trial evaluated anti-CD20 antibody efficacy and anti-nephrin antibody prevalence in MCD-IgAN, suggesting therapeutic options and biomarkers.

Key Points

The aim was to assess the efficacy of anti-CD20 monoclonal antibodies and the prevalence of anti-nephrin antibodies in MCD-IgAN patients.
Retrospective cohort study of MCD-IgAN patients comparing anti-CD20 mAbs and steroids treatment.
Efficacy measurements included remission rates and recurrence-free periods.
Assessment of anti-nephrin antibody prevalence and its association with disease outcomes.
Total remission rates were comparable between both groups, but anti-CD20 mAbs group had a longer recurrence-free period (30.4 months vs. 17.1 months, p=0.01).
Fewer adverse events and lower re-hospitalization rates were reported in the anti-CD20 mAbs group.
Higher levels of anti-nephrin antibodies (>150 ng/mL) were linked to an increased recurrence hazard (HR=3.93, 95% CI: 1.18-13.13).

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/6a192c67fab5b468c4415461 https://doi.org/10.1016/j.ekir.2026.106622

View Full Paper

Ask AI

Bookmark

May 29, 2026Kidney International ReportsOpen Access

Anti-CD20 therapies and anti-nephrin autoantibodies in IgA nephropathy with minimal change disease

View Full Paper

Ask AI

Bookmark

Authors

YLYu Liang ZYZerui Yang XYXiaohan Yuan

Discussion

Member takes

Overview

Randomized trial evaluated anti-CD20 antibody efficacy and anti-nephrin antibody prevalence in MCD-IgAN, suggesting therapeutic options and biomarkers.

Key Points

The aim was to assess the efficacy of anti-CD20 monoclonal antibodies and the prevalence of anti-nephrin antibodies in MCD-IgAN patients.
Retrospective cohort study of MCD-IgAN patients comparing anti-CD20 mAbs and steroids treatment.
Efficacy measurements included remission rates and recurrence-free periods.
Assessment of anti-nephrin antibody prevalence and its association with disease outcomes.
Total remission rates were comparable between both groups, but anti-CD20 mAbs group had a longer recurrence-free period (30.4 months vs. 17.1 months, p=0.01).
Fewer adverse events and lower re-hospitalization rates were reported in the anti-CD20 mAbs group.
Higher levels of anti-nephrin antibodies (>150 ng/mL) were linked to an increased recurrence hazard (HR=3.93, 95% CI: 1.18-13.13).

Cite This Study

Liang et al. (2026) studied this question.

synapsesocial.com/papers/6a192c67fab5b468c4415461 https://doi.org/10.1016/j.ekir.2026.106622

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark